Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia

Schizophrenia Research

Volumn 4, Issue 2, 1991, Pages 121-156

  Deutch, Ariel Y ^a,b   Moghaddam, Bita ^a,b   Innis, Robert B ^a,b   Krystal, John H ^a,b   Aghajanian, George K ^a,b   Bunney, Benjamin S ^a,b   Charney, Dennis S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

(Schizophrenia); 5 HT2 serotonin receptor; Atypical antipsychotic drug; Clozapine; D2 dopamine receptor; Dopamine; Raclopride; Serotonin

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR; FLUPERLAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SEROTONIN; TIOSPIRONE; ZOTEPINE;

CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BRAIN; HUMAN; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026011938     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/0920-9964(91)90030-U     Document Type: Article

References (342)

1. Clozapine — pharmacokinetic investigations and biochemical effects in man
2. Pharmacological characterization of dopaminergic ‘autoreceptors’ by microiontophoretic single-cell recording studies
3. Remoxipride and haloperidol in schizophrenia: A double-blind MC study
4. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment
5. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpir ide or chlorpromazine
6. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients — relationship to drug concentrations
7. Paradoxical reaction to L-dopa in schizophrenic patients
8. 2 receptors: an autoradiographic analysis in rat brain
9. Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists
10. 2-dopamine receptor using a novel high affinity radio-iodinated probe
11. 2-dopamine receptor binding subunit in several mammalian tissues and species by photoaffinity labelling
12. Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system
13. 3H]SCH 23390 binding to dopamine receptors in vitro in mouse brain
14. Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of t he D1 receptor
15. Lack of efficacy of D-propranolol in akathisia
16. Das klinische Wirkungsbid von Clozapine (Untersuchung mit dem AMP-System)
17. 5H-dibenzo-(b,e)-(1,4)-diazepine) im Vergleich su Levomepromazin
18. Effect of neuroleptics on positive and negative symptoms and the deficit state
19. Chronic haloperidol causes persistent increase in 3,4-dihydroxyphenylacetic acid (DOPAC) concentration in the substantia nigra but not in the ventral tegmental area
20. Evidence for dopamine autoreceptors controlling dopamine synthesis in the substantia nigra
21. 2 receptors in the medial prefrontal cortex: microiontophoretic studies
22. Differential effect of typical and atypical antipyschotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells: a microiontophoretic study
23. 3 receptors in the medial prefrontal cortex: a microiontophoretic study
24. 3 receptor antagonist, fails to alter the number of spontaneously active midbrain dopamine neurons
25. 2 receptors in rat medial prefrontal cortex
26. Pharmacological profile of ritanserin: A very specific central serotonin S2 antagonist
27. Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system
28. Preferential effect of noncataleptogenic neuroleptics on the mesocortical dopaminergic function
29. A double blind comparative multicentre study of remoxipride B.I.D. and T.I.D. in comparison with haloperidol T.I.D. in schizophrenia
30. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics
31. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients
32. Increased vertical axon numbers in cingulate cortex of schizophrenics
33. Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats
34. Regional and laminar distribution of the dopamine and serotonin innervation in the macaque cerebral cortex: a radioautographic study
35. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia
36. D1 receptors function to suppress the activation of tuberoinfundibular dopamine neurons
37. 2 receptor blocking agent
38. Das klinische Wirkungsspektrum eines neuen Dibenzodiazepin-Derivats
39. Melperone in the treatment of schizophrenia
40. A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale the CPRS
41. In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist
42. 3 receptors in rat striatum
43. 2 receptors present in a rat pituitary adenoma and in transplantable rat pituitary tumors 7315a and MtTW15
44. 1 receptor agonist and antagonists
45. Cocaine increases extracellular dopamine in rat nucleus accumbens and ventral tegmental area as shown by in vivo microdialysis
46. Comparison of sulpiride and chlorpromazine in psychoses
47. Double blind trial of L-dopa in chronic schizophrenia
48. Anteroposterior gradients in cerebral glucose use in schizophrenia and affective disorders
49. Effects of acute and chronic neuroleptic treatment on the activity of midbrain dopamine neurons
50. Antipsychotic drugs and central dopaminergic neurons: a model for predicting therapeutic efficacy and the incidence of extrapyramidal side effects
51. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic activity
52. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity
53. 2 dopamine receptor cDNA
54. 2 sites
55. 3H]N-propylnorapomorphine
56. The current status of the dopamine hypothesis
57. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain
58. Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats
59. Combined drug therapy of chronic schizophrenics
60. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis. An open dose finding study
61. Differential response to amphetamine in schizophrenia
62. Effect of serotonin antagonist in schizophrenia: A pilot study with setoperone
63. Dendritic release of dopamine in the substantia nigra
64. 2 dopamine receptor in rat and bovine caudate nucleus
65. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
66. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons
67. Population response of midbrain dopamine neurons to neuroleptics: further studies on time course and nondopaminergic neuronal influences
68. An early phase II clinical trial of BW 234U in the treatment of acute schizophrenia in newly admitted patients
69. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity
70. Amperozide: A new pharmacological approach in the treatment of schizophrenia
71. The risks and benefits of clozapine vs. chlorpromazine
72. D1 dopamine receptor—the search for function: critical evaluation of the D1-D2 dopamine receptor classification and its functional implications
73. 4 receptor: naughty, but nice
74. Dopamine-sensitize adenylate cyclase in mammalian brain a possible site of action of antipsychotic drugs
75. Indoleamine antagonists: relative potencies as inhibitors or tryptamine-and 5-hydroxytryptophan-evoked responses
76. In vivo potencies of antipsychotic drugs in blocking apha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action
77. Biochemical and behavioral effects of sigma and PCP ligands
78. Efficacy, safety and tolerability of raclopride, a specific D2 receptor blocker, in acute schizophrenia: an open trial
79. 1 sites
80. 3 antagonist GK38032F on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain
81. Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia
82. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
83. Influence of ascending serotonergic pathways on glucose use in the conscious rat brain. I Effects of electrolytic or neurotoxic lesions of the dorsal raphe and/or median raphe nucleus
84. Influence of ascending serotonergic pathways on glucose use in the conscious rat brain. II Effects of electrical stimulation of the rostral raphe nuclei
85. Interactions of dopamine with other neurotransmitters in the rat substantia nigra: a possible functional role of dendritic dopamine
86. Low dose bromocriptine A study of acute effects in chronic medicated schizophrenics
87. 2 receptor: two molecular forms generated by alternative splicing
88. Effects of the D1 agonist SKF-38393 combined with haloperidol in schizophrenic patients
89. 3H]SCH 23390 binding sites in human prefrontal cortex (Brodmann's area 9)
90. 1 dopamine receptor
91. 2 dopamine receptors in the human brain: heterogeneity based on differences in guanine nucleotide effect on agonist binding, and their presence on corticostriatal nerve terminals
92. Clozapine-induced agranulocytosis, a genetic and epidemiologic study
93. Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics
94. Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons
95. Accumulation of L-DOPA in the median eminence: an index of tuberoinfundibular dopaminergic nerve activity
96. Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenia
97. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients
98. The determinants of stress-induced activation of the prefrontal cortical dopamine system
99. Telencephalic projections of the A8 dopamine cell group
100. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress
101. Striatal heterogeneity in responsiveness to acute neuroleptic challenge: correlation with mesencephalic dopamine afferent sources
102. The neostriatum viewed orthogonally
103. A 5-HT receptor in the central nervous system positively coupled with adenylate cyclase, is antagonized by ICS 205 930
104. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system
105. Controlled trial of sulpiride in chronic schizophrenic patients
106. 11C-raclopride
107. Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
108. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
109. An open trial of raclopride in acute schizophrenia
110. The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase
111. Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain
112. Rimcazole (BW 234U), a novel antipsychotic agent whose mechanism of action cannot be explained by a direct blockade of postsynaptic dopaminergic recep tors in brain
113. Clonidine improves memory function in schizophrenia independently from change in psychosis
114. Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia?
115. Multispectral analysis of clozapine
116. Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs
117. Imaging neuronal biochemistry by emission computed tomography: focus on neuroreceptors
118. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors
119. Heterogeneities in the dopamine neuron systems and dopamine co-transmission in the basal ganglia and relevance of receptor-receptor interactions
120. Benzodiazepines: potentiation of a GABA inhibitory response in the dorsal rephe nucleus
121. Effect of antipsychotic drugs on the firing of dorsal raphe cells. I. Role of edrenergic system
122. A mechanism for the involvement of colocalized neuropeptides in the actions of antipsychotic drugs
123. Carecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydro xylase
124. Bromocriptine in the treatment of neuroleptic-resistant schizophrenia
125. Thymosthenic agents, a novel approach in the treatment of schizophrenia
126. Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia
127. The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: Results of an open study
128. 2 antagonist, and haloperidol in cebus monkeys
129. The effect of l-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs
130. Sulpiride and haloperidol in schizophrenia: a double blind cross over study of therapeutic effect, side effects and plasma concentrations
131. 2 dopamine recptor isoforms
132. The role of 5HT2 receptor blockade on amphetamine (AMP) inhibition of dopamine (DA) cell firing
133. Ritanserin increases spontaneous activity of A9 and A10 dopamine neurons
134. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity
135. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recordi ng
136. Neuroleptic-sensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia nigra, pars c ompacta of the cat
137. The significance of dendritic release of transmitter and protein in the substantia nigra
138. Effects of amperozide a putative antipsychotic drug on rat midbrain dopamine neurons recorded in vivo
139. Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Debenzodiazepingruppe
140. Activation of tuberoinfundibular dopamine neurons following acute administration of stypical antipsychotics
141. Disruption of serotonergic function inhibits the clozapine-induced activation of tuberoinfundibular dopamine neurons
142. A comparison of the effects of haloperidol on dopamine turnover in the striatum, olfactory tubercle, and median eminence of the rat brain
143. Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat
144. Basic biology of clozapine: electrophysiological and neuroendocrinological studies
145. 3H-3-(3-hydroxyphenyl)-N-(1 -propyl) piperidine
146. Amperozide — A new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behavior
147. Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: a dose-range study
148. 3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat br ain
149. Effects of remoxipride and some related new substitutrd salicylamides on rat brain receptors
150. 2 receptors
151. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental area (A10) and nigrostriatal (A9) dopamine neurons
152. Clinical evaluation of sulpiride in schizophrenic patients — A double blind comparison with chlorpromazine
153. Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET)
154. C1-943, a potential antipsychotic agent. I. Preclinical behavioral effects
155. Increased utilization of dopamine in the nucleus accumbens but not in the cerebral cortex after dorsal raphe lesions in the rat
156. Opposite changes in dopamine utilization in the nucleus accumbens and the frontal cortex after electrolytic lesion of the median raphe in the rat
157. 3H]SCH 23390-labelled D1 dopamine receptors in rat striatum
158. The history of clozapine
159. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemist ochemistry combined with retrograde tracing
160. 1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients
161. Clozapine: Antipsychotic activity in treatment-resistant schizophrenics
162. 2 recognition sites
163. 3 recognition sites: fact or artifact?
164. Comparison of the effects of D-1 and D-2 dopamine receptor agonists on neurons in rat caudate-putamen: an electrophysiological study
165. Dopamine release in nucleus accumbens and striatum by clozapine: simultaneous monitoring by in vivo electrochemistry
166. SCH23390 — the first selective dopamine D1 antagonist
167. Effect of l-dopa in schizophrenia
168. Double blind controlled study of l-dopa therapy in schizophrenia
169. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia
170. SCH23390, a potential benzamide antipsychotic with unique interactions on dopaminergic systems
171. Clinical evaluation of therapeutic effects of supiride, a neuroleptic drug, on schizophrenia by double blind controlled test
172. 5-HT and anxiety
173. A controlled clinical trial of tiosperone in schizophrenia
174. The development of new antipsychotic drugs: towards a new strategy in the management of chronic psychoses
175. Pharmacology of resperidone (R 64 766), a new antipsychotic with serotonin-S2 antagonistic properties
176. Adverse effects of anticholinergic considerations
177. Acute and chronic treatments with neuroleptics: similarities and differences in their action on nigrostriatal, mesolimbic, and mesocortical dopamenerg ic neurons
178. Somatodendritic release of endogenous dopamine: in vivo dialysis in the A10 dopamine region
179. Clozapine for the treatment-resistant schizophrenic
180. Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial
181. Multiple receptors for dopamine
182. 3H]GR65630 in rat brain using quantitative autoradiography
183. 3H]GR65630, to rat area postrema, vagus nerve and the brains of several species
184. Anatomical neuropathology in schizophrenia: post-mortem findings
185. The neuropathology of schizophrenia
186. The effects of haloperidol on synaptic plasticity in rat's medial prefrontal cortex
187. 3H-raclopride
188. Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with parachlorphenylalanine
189. 3 antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons
190. Long term effect of clozapine in schizophrenia A retrospective investigation of 216 patients treated with clozapine for up to 7 years
191. 1-noradrenergic receptors demonstrated by in vivo voltammetry
192. Remoxipride — a Canadian multicentre clinical trial
193. 3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine
194. 3H]-1-[1-(2-thienyl)cyclohexyl]piperidine
195. Novel antipsychotic drugs share high affinity for sigma receptors
196. Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity
197. The distribution of tyrosine hydroxylase-immunoreactive fibers in primate neocortex is widespread by regionally specific
198. The dopaminergic innervation of monkey prefrontal cortex: a tyrosine hydroxylase immunohistochemical study
199. Biochemical profile of risperidone, a new antipsychotic
200. 2 antagonist. Mol. Pharmacol. 27, 600-611.
201. 3H]raclopride
202. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopam ine interaction
203. The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years
204. An open study of remoxipride, a benzamide derivative, in schizophrenia
205. Opposite influences of dopaminergic pathways to the prefrontal cortex or the septum on the dopaminergic transmission in the nucleus accumbens. An in vivo voltammetric study
206. Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency
207. Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers
208. 1B receptors in biopsied and post-mortem human brain
209. 3H]-N-allylnormetazocine bind to different sites in the mouse brain
210. An open multicentre study of the treatment of florid schizophrenia with remoxipride
211. A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia
212. 2 dopamine receptor mRNA in rat brain
213. 2 receptor mRNA in primate brain: an in situ hybridization histochemistry study
214. Ritanserin in tardive dyskinesia: A double blind crossover study versus placebo
215. Enhancement of dopamine metabolism in rat brain frontal cortex: a common effect of chronically administered antipsychotic drugs
216. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia
217. The dopamine hypothesis of schizophrenia
218. i values
219. C1-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity
220. 2 receptor in the rat brain by in situ hybridization histochemistry
221. 1-adrenoceptors in brain
222. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment
223. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism
224. 3H]SCH 23390 binding
225. Evaluation of antipsychotic activity in schizophrenic patients
226. Utilization of microdialysis for assessing the release of dopamine in mesotelencephalic dopamine systems following clozapine and other antipsychotic drugs
227. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study
228. Risperidone: Treatment of schizophrenic patients with negative symptoms
229. 2 receptors produced by alternative RNA splicing
230. 1 dopamine receptor linked to adenylyl cyclase activation
231. BMY 13859: Summary of results from initial clinical trials
232. 2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices
233. Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei
234. Clinico-pharmacological studies of sulpiride
235. Differences in dopamine release and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis
236. Novel dopamine D-2 antagonists for the treatment of schizophrenia
237. The selective dopamine D-2 receptor antagonist raclopride discriminates between dopamine-mediated motor function
238. Clinical effects of L-dopa on schizophrenia
239. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics
240. Identification of a D2 receptor subtype which elevates intracellular calcium
241. Does cholecystokinin colocalize with dopamine in the human substantia nigra?
242. Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine or human cortex: evidence for species differe nces in brain serotonin receptors
243. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors
244. Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function
245. 2 Binding sites
246. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency
247. Risperidone: A new approach in the treatment of schizophrenia
248. Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years
249. C1-943, a potential antipsychotic agent. II. Neurochemical effects
250. Effect of 6-hydroxy-dopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat
251. Effect of lesion of cortical dopamine terminals on subcortical dopamine in rats
252. A clinical and pharmacodynamic evaluation of supiride
253. 2 binding affinity
254. 2 receptor blocker
255. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro
256. Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys
257. Bromocriptine
258. The neurochemistry of midbrain dopamine systems
259. Antiparkinsonian drug abuse: Eight case reports
260. The effect of chronic neuroleptic administration on cerebral dopamine receptor function
261. 2 antagonists modulate the effects of D-2 dopamine receptor blockade
262. 3H]SCH 23390
263. 3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in the rat
264. Presence of cholecystokinin mRNA in dopamine cells in the ventral mesencephalon of a human with schizophrenia
265. 3 receptor pharmacophore
266. 3H]dopamine
267. Clozapine
268. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography
269. Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics
270. Imaging of neurotransmitter receptors in the living human brain
271. Dopamine receptors and the dopamine hypothesis of schizophrenia
272. Dopamine receptors in brain and periphery
273. Brain receptors for antipsychotic drugs and dopamine: direct binding assay
274. Antipsychotic drug doses and neuroleptic/dopamine receptors
275. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases
276. 3H]raclopride: Implications for positron emission tomography of the human brain
277. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain
278. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study
279. A subtype
280. Clozapine, chlorpromazine and placebo in newly-hospitalized, acute schizophrenic patients: A controlled, double-blind comparison
281. Treatment of chronic schizophrenia with cyproheptadine
282. Mesencephalic dopaminergic neurons: role in the general economy of the brain
283. Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptics in schizophrenia. Implications for a neuropharmacological model
284. Reversal of some therapeutic effects of an antipsychotic agent by an antiparkinsonism drug
285. Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: Implications for psychobiological subtyping
286. 3H]SKF10.047 binding in rat and mouse brain: further evidence for phencyclidine/ ‘sigma opiate’ receptor commonality
287. Differential effects after repeated administration with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopaminergic neurones in rats
288. Abuse of the antiparkinson drugs: a review of the literature
289. Antischizophrenic drugs: Affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects
290. Antischizophrenic drugs and brain cholinergic receptors
291. 3H]haloperidol
292. 3 receptor antagonist, on A9 and A10 dopamine cells
293. 1 receptor encoded by an intronless gene on chromosome 5
294. Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons
295. Receptor binding properties of amperozide
296. Naloxone-inaccesible receptor in rat central nervous system
297. 3H]haloperidol binding in guinea pig membranes
298. New neuroleptics and experiment antipsychotics in schizophrenia
299. Trihexiphenidyl treatment of negative schizophrenic symptoms
300. Cholinergic hyperactivity and negative schizophrenic systoms: A model of cholinergic/dopaminergic interactions in schizophrenia
301. Treatment of negative schizophrenic symptoms with trihexiphenidyl
302. Potential antipsychotic BMY 14802 selectively binds to sigma sites
303. Behavioral pharmacology of the benzodiazepines
304. Attenuation of induced anxiety in rats by chlordiazepoxide: role of raphe dorsalis benzodiazepine binding sites and serotonergic neurons
305. Variation in the ability of neuroleptics to block the inhibitory influence of dopaminergic neurons on the activity of cells in the rat prefrontal cortex
306. 2 dopamine receptor subtype
307. 3 receptors in rat dorsal root ganglion (DRG) cells
308. Interactions between dopamine and 5HT3 receptors suggest new treatments for psychosis and drug addiction
309. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study
310. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy)dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug
311. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug
312. Biochemical instability in schizophrenia II: The serotonin and gamma-aminobutyric acid systems
313. 2 dopamine receptor mRNA level
314. Mianserin hydrochloride: peripheral and central effects in relation to antagonism against 5-hydroxytryptamine and tryptamine
315. Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist
316. 3 receptors in the mouse CNS
317. 3H]ICS 205–930
318. Serotonergic modulation of mesolimbic and frontal cortical dopamine neurons
319. Serotonin-dopamine interactions in the nigrostriatal system
320. On the relevance of preferential increase of mesolimbic vs. striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs
321. 2 receptors of normal human brain in vitro
322. Implications of normal brain development for the pathogenesis of schizophrenia
323. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood fow evidence
324. Sigma receptors in post-mortem human brains
325. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat
326. Differential effects of typical and atypical antipsychotic drugs on A9 and A10 dopamine neurons
327. Effects of supiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography
328. 2) receptors in the rat brain
329. Results of a multicenter AMDP study with fluperlapine in schizophrenic patients
330. Fluperlapine - a potential successor to clozapine
331. Stimulation of D2 dopamine receptors decreases intracellular calcium levels in rat pituitary cells but not striatal synaptosomes: a flow cytometric study using Indo-1
332. The neurochemistry of dopamine
333. A neurochemical heterogeneity of the rat striatum as measured by in vivo electrochemistry and microdialysis
334. The effect of L-dopa on schizophrenia
335. Profiles of clinical efficacy and pharmacological action of zotepine
336. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis
337. 1 dopamine receptors